Amniocentesis
Amniocentesis is a prenatal diagnostic procedure in which a small sample of amniotic fluid is collected using a thin needle under continuous ultrasound guidance. The sample can be used for genetic and chromosomal testing when a more definitive diagnosis is needed during pregnancy.
Amniocentesis is an invasive prenatal diagnostic test used to examine amniotic fluid surrounding the fetus. The fluid contains fetal cells and other substances that can provide valuable information about certain chromosomal, genetic and other conditions.
Amniocentesis may be recommended when there is a specific reason to obtain diagnostic information about the fetus. It may be considered after an increased-chance prenatal screening result, an ultrasound finding suggesting a possible genetic or chromosomal condition, a previous pregnancy affected by a genetic condition, or a known family history of a condition that can be investigated through prenatal testing.
Amniotic fluid obtained during amniocentesis can be tested for chromosomal conditions such as Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18) and Patau Syndrome (Trisomy 13). Depending on the clinical indication, additional genetic investigations may also be considered.
NIPT or cell-free DNA testing is a screening test rather than a diagnostic test. When NIPT indicates a high chance of a chromosomal condition, amniocentesis may be discussed as one option for diagnostic confirmation. A fetal medicine specialist can explain the screening result and available diagnostic choices before the procedure.
Certain fetal structural abnormalities or ultrasound markers may increase the suspicion of a chromosomal or genetic condition. In such situations, amniocentesis may provide diagnostic information that can help clarify the underlying cause of the ultrasound findings.
Amniocentesis is generally performed after 15 weeks of pregnancy. The exact timing depends on the clinical indication, gestational age, ultrasound findings and the type of genetic testing being considered.
The procedure is performed under ultrasound guidance. The fetal position, placenta and amniotic fluid are first assessed. After cleaning the abdomen, a very thin needle is carefully passed through the abdominal wall and uterus into the amniotic cavity while its position is monitored by ultrasound. A small amount of amniotic fluid is then collected and sent to the laboratory for the requested tests.
Yes. Ultrasound guidance is used throughout the procedure to identify the fetus, placenta and an appropriate pocket of amniotic fluid and to monitor the needle position. This allows the procedure to be performed in a controlled and carefully planned manner.
Most women describe amniocentesis as uncomfortable rather than severely painful. The experience can vary between individuals. The procedure itself is usually brief, although the complete appointment also includes ultrasound assessment, counselling and preparation.
The laboratory tests performed depend on the reason for amniocentesis. Chromosome analysis may be requested, and rapid testing may be used for selected chromosomal conditions. Depending on the clinical situation, chromosomal microarray or targeted molecular genetic testing may also be considered.
Some laboratories offer rapid testing on amniotic fluid for common chromosomal abnormalities. This can provide preliminary information before more comprehensive chromosome or genetic testing is completed. The exact tests and turnaround times depend on the laboratory and clinical indication.
Chromosomal microarray can detect certain chromosome changes that may not be identified by conventional chromosome analysis. Whether microarray is appropriate depends on the ultrasound findings, reason for testing and specialist genetic counselling.
When there is a known genetic condition in the family or a specific inherited disorder is suspected, amniotic fluid may be tested using targeted genetic methods. The exact test is selected according to the suspected condition and the family's genetic information.
In selected pregnancies, amniotic fluid may also be examined for evidence of certain fetal infections. This is not a routine indication for every amniocentesis and is considered when clinical history, maternal testing or ultrasound findings raise a specific concern.
NIPT is a non-invasive screening test performed using maternal blood, while amniocentesis is an invasive diagnostic procedure involving collection of amniotic fluid. NIPT estimates the chance of selected chromosomal conditions, whereas diagnostic testing through amniocentesis can provide more definitive information for the conditions being tested.
Chorionic villus sampling (CVS) and amniocentesis are both invasive prenatal diagnostic procedures. CVS obtains a sample of placental tissue and is generally performed earlier in pregnancy, while amniocentesis obtains amniotic fluid and is generally performed after 15 weeks. The most appropriate option depends on gestational age, clinical findings and the condition being investigated.
Amniocentesis may be discussed when prenatal screening indicates an increased chance of a chromosomal condition, when an ultrasound examination identifies concerning fetal findings, when there has been a previous pregnancy affected by a genetic or chromosomal condition, or when there is a known family history of a specific inherited disorder.
Amniocentesis can be performed in selected twin or multiple pregnancies when diagnostic testing is indicated. The procedure requires careful ultrasound planning because each fetus and its individual amniotic sac must be correctly identified before sampling.
Amniocentesis is generally a well-established procedure, but it is an invasive test and carries a small risk of complications. These may include miscarriage, leakage of amniotic fluid, bleeding, infection or the need for repeat testing in uncommon circumstances. The individual risk can vary according to gestational age, pregnancy type and clinical circumstances.
A small risk of pregnancy loss is associated with amniocentesis. Published patient guidance commonly estimates the procedure-related risk in a singleton pregnancy at around 1 in 200, although the actual risk varies between centres and individual clinical circumstances. Your fetal medicine specialist should discuss the locally relevant risk before the procedure.
Your blood group and Rh status may be checked before the procedure. If you are RhD negative, your healthcare team may recommend anti-D immunoglobulin after an invasive prenatal procedure according to local clinical protocols.
Mild abdominal discomfort or cramping can occur after amniocentesis. Your fetal medicine team will provide individualized instructions regarding activity and follow-up. Contact your maternity or medical team promptly if you experience significant or persistent abdominal pain, vaginal bleeding, fluid leaking from the vagina, fever or contractions after the procedure.
The time required to receive results depends on the type of test performed. Some rapid chromosome tests may provide preliminary results within a few days, while conventional chromosome analysis, microarray or specific genetic tests can take longer. Your laboratory or fetal medicine team will explain the expected reporting time for your particular test.
A normal result provides important information about the conditions included in the test, but no prenatal test can exclude every possible genetic, developmental or structural condition. Recommended ultrasound examinations and routine pregnancy care should continue according to your individual pregnancy plan.
If testing identifies a chromosomal or genetic condition, the result can be discussed in detail with a fetal medicine specialist and, when appropriate, a genetic counsellor. Additional ultrasound assessment may help determine whether there are associated fetal findings and can assist with individualized pregnancy counselling and planning.
Before amniocentesis, parents should understand why the test is being offered, what condition is being investigated, what information the test can and cannot provide, when results are expected and the potential risks of the procedure. This helps families make an informed decision about prenatal diagnostic testing.
Ultrasound assessment is an important part of the amniocentesis process. A detailed review of fetal anatomy, placenta, amniotic fluid and fetal position helps the specialist plan the procedure and can also provide important clinical information about the pregnancy.
At Promise Fetal Medicine & Pregnancy Scan Centre in Jalandhar, amniocentesis may be considered when prenatal diagnostic testing is clinically indicated. Specialist ultrasound assessment, pre-procedure counselling and guidance regarding appropriate genetic testing can help parents understand their available options.
If you have received a high-risk NIPT result, an abnormal ultrasound finding, a positive prenatal screening result or have a known family history of a genetic condition, a fetal medicine consultation can help determine whether amniocentesis or another prenatal diagnostic test may be appropriate for your pregnancy.
Ensure Your Baby’s Health with Expert Fetal Care and Advanced Sonography
Book Your Consultation Today for a Safe and Healthy Pregnancy
Amniocentesis is a prenatal diagnostic procedure in which a small sample of amniotic fluid is collected using a fine needle under ultrasound guidance. The fluid contains fetal cells and other substances that can be analyzed for certain chromosomal and genetic conditions and, when clinically indicated, other fetal conditions. Amniocentesis is generally performed during the second trimester, although timing depends on the clinical indication. It may be offered when prenatal screening or ultrasound findings indicate an increased risk of a genetic or chromosomal condition, or when there is a relevant family or pregnancy history. At Promise Fetal Medicine & Pregnancy Scan Centre in Jalandhar, amniocentesis is performed with detailed counseling and ultrasound guidance when appropriate.
Director and Chief Fetal Medicine Specialist
Baby's Journey Through Pregnancy
